Here are seven new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists.
Adefovir dipivoxil tablet: Apotex Corp has discontinued 10 milligram Adefovir Dipivoxil tablets, an antiviral medication used to treat hepatitis B infection. No further details were provided.
Clindamycin phosphate; benzoyl peroxide gel: Teva Pharmaceuticals has discontinued the combination topical gel containing clindamycin phosphate and benzoyl peroxide (25 mg/1 gram; 10 mg/1 gram) for dermatological use. The decision was based on business reasons.
Esterified estrogens tablet: Pfizer has discontinued Menest tablets in multiple strengths, 0.3 mg, 0.625 mg, 1.25 mg and 2.5 mg, used in endocrinology and metabolism treatments.
Fluocinolone acetonide intravitreal treatment: Ani Pharmaceuticals’ Yutiq 0.18 mg intravitreal implant, used for chronic non-infectious uveitis affecting the posterior segment of the eye, is on long-term back order with no estimated resupply date. Alternative implants such as Iluvien 0.19 milligram and Bausch Health’s Retisert are available but differ in delivery and dosage.
Irinotecan hydrochloride injection: Fresenius Kabi and Teva Pharmaceuticals are discontinuing various strengths of irinotecan hydrochloride injections used in oncology. Fresenius Kabi’s 40 mg/2 milliliter and 100 mg/5 milliliter vials were discontinued and Teva’s 20 mg/1 milliliter injections are expected to be unavailable beyond mid-September to mid-October.
Mometasone furoate aerosol for oral inhalation: Organon reports a shortage of Asmanex HFA inhalers in 50 mcg and 100 mcg strengths due to increased demand. The company expects to restock the products by mid-August. Asmanex Twisthaler and 200 mcg inhalers remain available.
Voriconazole tablet: Pfizer has discontinued Vfend 50 mg tablets; it is an antifungal medication used to treat serious infections.
